Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

计划入组 187 人 · 首次发布于 2013 年 11 月 25 日

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

计划入组 187 人 · 首次发布于 2015 年 11 月 20 日

Bipolar Enbloc Versus Thulium-Yag Enbloc Resection of Bladder Tumors

计划入组 50 人 · 首次发布于 2023 年 11 月 7 日

Mabion-HER2_ADC(Mabion)

MY012 (Mabylon)

MAbCo-19

Mabion SA

Poland

ASSA ABLOY LIMITED

United Kingdom

HOSPITAL PABLO TOBON URIBE

Colombia

Mabloc and Instituto Butantan Partner to Develop First-in-Class Monoclonal Antibody Therapy for Yellow Fever

Protalix BioTherapeutics Appoints Gilad Mamlok as New CFO to Drive Growth Strategy

Mabylon Advances MY006 Peanut Allergy Treatment to Phase Ib Following Positive Safety Data